• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Clin Exp Nephrol . Mortality comparison between the COVID-19 Omicron variant and influenza among patients with end-stage kidney disease: a nationwi

tetano

Editor, Senior Moderator
Clin Exp Nephrol


. 2026 Jan 23.
doi: 10.1007/s10157-026-02814-z. Online ahead of print.
Mortality comparison between the COVID-19 Omicron variant and influenza among patients with end-stage kidney disease: a nationwide population-based retrospective cohort study

Tomoyuki Fujikura[SUP] 1 [/SUP], Koichi Miyashita[SUP] 2 [/SUP], Hironao Hozumi[SUP] 2 [/SUP], Yuri Ishino[SUP] 3 [/SUP], Naoko Katahashi[SUP] 4 [/SUP], Naoko Tsuji[SUP] 5 [/SUP], Sayaka Ishigaki[SUP] 5 [/SUP], Takamasa Iwakura[SUP] 3 [/SUP], Shinsuke Isobe[SUP] 5 [/SUP], Kazuki Furuhashi[SUP] 2 [/SUP], Naro Ohashi[SUP] 4 [/SUP], Toshiyuki Ojima[SUP] 6 [/SUP], Takafumi Suda[SUP] 2 [/SUP], Hideo Yasuda[SUP] 3 [/SUP]


Affiliations
Abstract

Background: Although the SARS-CoV-2 Omicron variant demonstrates lower mortality than previous variants in the general population, its impact on patients with end-stage kidney disease (ESKD) remains concerning. Substantial mortality has been reported in patients with ESKD during the Omicron period; however, comparing this with influenza mortality could provide insights into COVID-19's true impact in this high-risk population.
Methods: Using the National Database of Health Insurance Claims of Japan, we conducted a retrospective cohort study of hemodialysis patients diagnosed with COVID-19 during the Omicron period (January 2022-March 2023) or influenza (September 2017-March 2023). The primary outcome was 30-day all-cause mortality. Overlap weighting based on propensity scores balanced confounding factors.
Results: We identified 53,047 COVID-19 and 35,808 influenza cases. After overlap weighting, the 30-day mortality rates were 3.4% for COVID-19 and 1.8% for influenza (hazard ratio
1.61 [95% CI 1.47, 1.77]). In subgroup analyses stratified by age, HRs were comparable across all age groups (20-49 years: 1.59 [0.81, 3.13]; 50-59 years: 1.43 [0.94, 2.17]; 60-69 years: 1.45 [1.15, 1.84]; 70-79 years: 1.68 [1.43, 1.96]; ≥ 80 years: 1.66 [1.45, 1.89]). The absolute risk differences (per 1,000 patients) across age groups were 1.7, 2.6, 6.2, 16.2, and 28.9 deaths, respectively.
Conclusions: In this nationwide study, COVID-19 Omicron variant was associated with significantly higher mortality than influenza in hemodialysis patients. Age-stratified analyses showed consistent relative risks but progressively larger absolute risk differences in older patients.

Keywords: Coronavirus disease 2019; Hemodialysis; Influenza; Mortality; Omicron.

 
Back
Top Bottom